Prophylactic vasopressor administration is commonly recommended to reduce maternal hypotension during spinal anaesthesia for caesarean section. Metaraminol has undergone limited investigation in obstetric anaesthesia for this purpose, particularly in comparison with phenylephrine. In this multicentre, randomised, double-blind, non-inferiority study, we compared prophylactic phenylephrine or metaraminol infusions, started immediately after spinal anaesthesia, in 185 women who underwent elective caesarean section. Phenylephrine was initially infused at 50 lg.min À1 , and metaraminol at 250 lg.min À1 . The primary outcome was the difference in umbilical arterial pH between groups; secondary outcomes included other neonatal acid-base measures, and maternal haemodynamic changes. The mean (SD) umbilical arterial pH was 7.28 (0.06) in the phenylephrine group vs. 7.31 (0.04) in the metaraminol group (p = 0.0002). The estimated mean (95%CI) pH difference of 0.03 (0.01-0.04) was above the pre-determined lower boundary of clinical non-inferiority, and also met the criterion for superiority. Umbilical artery lactate concentration was 2.8 (1.2) mmol.l À1 in the phenylephrine group vs. 2.3 (0.7) mmol.l À1 in the metaraminol group (p = 0.0018). Apgar scores did not significantly differ between groups. There was a higher incidence of hypotension, defined as systolic arterial pressure < 90% baseline, in the phenylephrine group; there was a higher incidence of hypertension and severe hypertension (systolic arterial pressure > 110% and > 120% baseline, respectively) in the metaraminol group. There was no significant difference between groups in the incidence of nausea, vomiting or maternal bradycardia. We conclude that, when used as an infusion to prevent hypotension after spinal anaesthesia for elective caesarean section, metaraminol is at least non-inferior to phenylephrine with respect to neonatal acid-base outcomes.
Introduction
Caesarean section is one of the most commonly performed surgical procedures; approximately 80-90% of elective caesarean sections in developed countries are conducted using spinal anaesthesia. Maternal hypotension is a frequent side effect of spinal anaesthesia, which can result in adverse maternal and fetal outcomes [1] . A number of methods to prevent hypotension have been studied, however, the administration of a sympathomimetic drug is now commonly recommended [2, 3] . A prophylactic infusion appears preferable [3] [4] [5] ; ephedrine has largely been replaced by phenylephrine, because of improved maternal outcomes and reduced neonatal acidosis when using phenylephrine [6, 7] .
Despite the widespread move away from ephedrine, there remain some unanswered questions in relation to the use of predominately a-adrenergic agents. Higher doses of phenylephrine may result in less stable maternal haemodynamic status, with reflex bradycardia and splanchnic venous dilation leading to reduced venous return and cardiac output, and an adverse effect on uterine blood flow [8, 9] .
Maintaining maternal blood pressure and heart rate, a surrogate marker of cardiac output, close to baseline are the usual primary goals of vasopressor prophylaxis [10] [11] [12] . The administration of drugs, other than ephedrine, with combined a-and b-adrenergic receptor agonist activity has been described, including noradrenaline [13] and metaraminol [14] [15] [16] [17] . Metaraminol appears to have advantages over ephedrine [14] , but there are few direct comparisons with phenylephrine, despite its long-standing use in non-obstetric practice [18] .
We hypothesised that use of a prophylactic metaraminol infusion to reduce maternal hypotension would not be inferior to phenylephrine infusion with respect to neonatal acid-base status. The aim of this randomised, double-blind, active control, parallel group, multicentre non-inferiority trial was to compare prophylactic infusions of phenylephrine and metaraminol in women undergoing elective caesarean section under spinal or combined spinal-epidural (CSE) anaesthesia with respect to the umbilical artery pH of the neonate. Secondary outcomes assessed included other neonatal blood gas values, as well as maternal symptoms and haemodynamic changes.
Methods
The study was conducted at King Edward Memorial Hospital for Women and Rockingham General Hospital. Ethical approval was obtained from the Women and Newborn Health Service, and all participants provided written consent. The trial was conducted between February 2013 and June 2015.
We recruited women of ASA physical status 1-2 and BMI 20-35 kg.m À2 with a singleton term pregnancy, scheduled for elective caesarean section under spinal or CSE anaesthesia. We excluded patients with diabetes, pre-eclampsia or other cardiovascular or cerebrovascular disease, a fetal abnormality or intra-uterine growth restriction. Women were excluded from subsequent analysis if an adequate sensory block of cold sensation up to T4 was not established with the spinal, administration of epidural drugs was required during the period until delivery of the fetus, or severe shivering made non-invasive blood pressure monitoring unreliable. Group assignment was determined by opening a sealed opaque envelope, numbered sequentially and prepared by secretarial staff using a computergenerated random number sequence in blocks of four. The study solution was prepared in a 100-ml bag by an anaesthetist who was otherwise uninvolved in the study, using 1 ml of phenylephrine 10 mg.ml À1 added to 99 ml of saline for a concentration of 100 lg.ml À1 , or 5 ml of metaraminol 10 mg.ml À1 added to 95 ml of saline for a concentration of 500 lg.ml
À1
. This was then decanted into a 20-ml syringe and placed in an Alaris GH Plus syringe pump (CareFusion Australia Pty Ltd, Sydney, Australia). The patient, attending anaesthetists and research staff involved in data collection and patient follow-up were blinded to the treatment group.
All women received premedication with 150 mg of ranitidine orally. On arrival in the operating room, the woman was positioned supine with left pelvic tilt provided by a wedge placed under the right hip, and allowed to rest for several minutes before measurements were taken. Baseline systolic arterial pressure and heart rate were determined from the mean of three readings that fell within 10% of each other, taken at least one minute apart.
The woman was then positioned sitting for the regional anaesthetic. A 16-G intravenous cannula was inserted, and crystalloid 10 ml.kg À1 was infused via a volumetric pump during the establishment of surgical anaesthesia. Spinal or CSE anaesthesia was performed at the L3-4 or 4-5 interspace, using a dose of 2.2-2.5 ml hyperbaric bupivacaine 0.5% together with 15 lg fentanyl. If a CSE technique was used, 5 ml of saline was injected into the epidural space before insertion of the epidural catheter. The woman was then returned to the supine position with pelvic tilt. A 30 ml.h À1 infusion of the study drug, equivalent to 50 lg.min À1 of phenylephrine or 250 lg.min À1 of metaraminol, was commenced at the time of spinal injection. Blood pressure and heart rate were measured at 1-minute intervals. If the systolic arterial pressure decreased to < 90% baseline at any time, the study drug infusion rate was increased in increments of 5 ml.h
. If the systolic arterial pressure fell to < 80% baseline, a bolus of 1 ml study drug was given. If, at any time, the systolic arterial pressure rose above baseline, the infusion rate was reduced in increments of 5 ml.h
. If a reading > 120% baseline occurred, the infusion was stopped until pressure returned to baseline or below, at which time it was recommenced at a rate reduced by 5 ml.h
. If the heart rate fell below 60 beats.min À1 , 0.4 mg glycopyrronium was administered intravenously.
The sensory block level was defined as any loss of cold sensation to ice, identifying the highest dermatome below that with normal sensation. The woman was requested to report symptoms such as nausea or syncope; if any systolic arterial pressure measurement was < 80% baseline, she was directly questioned about symptoms.
Monitoring continued until delivery of the fetus, at which point the study ended. At birth, arterial and venous blood samples were taken from a doubleclamped segment of the umbilical cord by the attending midwife. Apgar scores were assessed by the neonatology team at 1 min and 5 min after birth.
A non-inferiority design based on the primary outcome of umbilical artery pH was used. Based on data derived from our hospital and a state healthlinked database, we expected a mean (SD) neonatal umbilical artery pH of healthy term neonates at elective caesarean birth under regional anaesthesia following prophylactic phenylephrine infusion of 7.29 (0.05). A non-inferiority margin of 0.03 was chosen, based on differences observed in trials at elective caesarean section comparing phenylephrine and ephedrine [7] . This implies that non-inferiority of metaraminol compared with phenylephrine was accepted if the lower bound of the two-sided 95%CI of the estimated difference in treatment effect was > À0.03.
To demonstrate non-inferiority of metaraminol compared with phenylephrine, with 90% power and one-sided a equal to 0.025, 63 patients per group would be required. In order to provide secondary data on the incidence of maternal hypotension, defined as a reduction in systolic arterial pressure to < 90% baseline, and with an expected rate of 70%, we calculated that 81 patients per group were required to demonstrate a non-inferiority margin of 18%, with approximately 80% power and a of 0.05 (PASS 2008; NCSS, Kaysville, Utah, USA). To allow for withdrawals and incomplete neonatal acid-base data, the total sample size was increased to 180. The primary analysis was by intention-to-treat, but to protect against the increased risk of type-1 error associated with intention-to-treat analysis in non-inferiority trials, a per-protocol analysis was also conducted.
Further secondary outcomes included other measurements of neonatal status and maternal variables including the incidence of severe hypotension (reduction in systolic arterial pressure < 80% of baseline), bradycardia (heart rate < 60 beats.min À1 ), hypertension (increase in systolic arterial pressure >110% of baseline), nausea and the total volume and dose of vasopressor required until delivery. Univariate comparisons between treatment groups were made using independent t-tests for continuous data or Mann-Whitney tests for non-continuous data; and by Chi-squared or Fisher's exact tests for categorical outcomes. The difference in umbilical artery pH between treatment groups was estimated using linear regression analysis, and summarised with estimated mean effect size and the associated two-sided 95%CI. Spinal segments from C5 to T5 were numbered 1-9 and analysed using the Mann-Whitney test to assess the block level. Statistical analysis was performed using SPSS version 20.0 statistical software (IBM Corp, Armonk, NY, USA); p values < 0.05 were considered statistically significant.
Results
The CONSORT diagram is shown in Fig. 1 . One hundred and eighty-six women were randomly allocated, with 95 in the phenylephrine group and 91 in the metaraminol group; however, one woman randomly allocated to the metaraminol group was missing a complete set of data, and was not included in the analysis. There were six protocol violations where the rate was not adjusted strictly as per protocol, four in the phenylephrine group and two in the metaraminol group; these women were included in the analysis. One hundred and seventy-eight women completed the study; however, because of missing arterial cord gas samples, only 157 had data available for the primary outcome analysis, with 82 in the phenylephrine group and 75 in the metaraminol group. Among the 28 women for whom there was an inadequate arterial cord gas sample, there was no association between missing arterial samples and baseline characteristics. The two groups were similar with regard to maternal characteristics, baseline systolic arterial pressure and surgical time from incision to delivery (Table 1) .
The mean (SD) umbilical arterial pH was 7.28 (0.06) in the phenylephrine group vs. 7.31 (0.04) in the metaraminol group ( Table 2 ). The estimated mean (95%CI) difference in arterial pH between the groups was 0.03 (0.01-0.04). The lower bound of the twosided 95%CI of the estimated difference in treatment effect was 0.014, above the pre-determined lower boundary of clinical non-inferiority of À0.03, indicating that metaraminol was non-inferior to phenylephrine. The lower bound of the two-sided 95%CI also exceeded zero, indicating the superiority of metaraminol compared with phenylephrine at maintaining umbilical artery pH (Fig. 2) .
The model was assessed for the influence of incision-to-delivery time, with no substantive change to the result. Data presented in the tables and in Fig. 2 are unadjusted.
Secondary outcomes were analysed by intentionto-treat. There was a reduced incidence of hypotension and an increased incidence of hypertension in the (Table 3) . A larger volume of vasopressor solution was used in the phenylephrine group, and there more rescue bolus doses were required. The incidence of nausea, vomiting and maternal bradycardia was similar between the two groups. Secondary neonatal outcomes differed between groups for umbilical vein pH and pO 2 , which were lower in the phenylephrine group, and for pCO 2 , which was higher in the phenylephrine group (Table 2) .
In the per-protocol analysis, there were 152 umbilical artery pH measurements available for analysis; results for the primary outcome were consistent with the intention-to-treat analysis.
Discussion
Although a-1 adrenergic agonists, in particular phenylephrine, have become the preferred vasopressor drugs for the prevention of spinal anaesthesia-induced systemic vasodilation and decrease in arterial pressure in obstetric anaesthesia, a number of other drugs have been investigated. In this study, we found that the mixed a-1 and b-adrenergic agonist, metaraminol, administered by variable rate infusion, was non-inferior to phenylephrine in relation to neonatal umbilical artery pH. A non-inferiority, rather than a superiority, study design was chosen as we hypothesised that metaraminol would have similar efficacy to phenylephrine, that is, be non-inferior, in relation to our primary outcome. Although the results unexpectedly indicate that metaraminol was superior to phenylephrine, the effect size was small and this should be interpreted with caution. The study results nevertheless suggest that the use of metaraminol as an alternative to phenylephrine in obstetric anaesthesia is appropriate. Preventing a substantial decrease in maternal blood pressure after spinal anaesthesia for caesarean section is considered fundamental to avoid maternal nausea, vomiting and syncope, as well as neonatal hypoxaemia and acidosis. Maintenance of maternal systolic arterial pressure at near-baseline values has been recommended [10] , and based on the dosing regimens used in this study, metaraminol was associated with less hypotension but more increases in blood pressure above baseline. The incidence of 'severe' hypotension was consistent with other studies describing a range of blood pressure decrease between 25-30% of baseline. A low incidence of severe hypotension of < 10% has been reported when phenylephrine is infused at high rates [10, 19] , but this occurs at the expense of reactive hypertension and bradycardia.
Maternal blood pressure is often used as the main surrogate marker of uteroplacental perfusion; however, maternal cardiac output is another important consideration [3] . Phenylephrine in high doses can cause a baroreceptor-mediated reflex bradycardia, a reduction in stroke volume due to increased afterload, and a shift of blood into the splanchnic venous circulation. In combination with decreased venous return, this can lead to a dose-dependent fall in cardiac output [20] . Although phenylephrine has almost no b-adrenergic activity, metaraminol has both a-1 and b-adrenergic activity [21] , which theoretically might help preserve cardiac output. Cardiac output and heart rate are closely linked, so despite a lack of evidence of differences in outcomes [22] , avoidance of bradycardia is also thought to be an important management aim [10] [11] [12] . We found that the groups did not differ significantly Figure 2 Mean (95%CI) of the estimated difference in umbilical arterial pH between metaraminol and phenylephrine. Metaraminol is associated with a higher umbilical arterial pH than phenylephrine. with respect to the incidence of bradycardia or the lowest maternal heart rate, as did similar comparative studies [16, 17] . Despite no evidence of outcome benefit compared with pure a-1 adrenergic agonists, theoretical advantages of drugs that have b-adrenergic activity include a smaller increase in uteroplacental vascular resistance [23] , better restoration of fetal haemodynamic status after fetal hypoxaemia [24, 25] and maintenance of cerebral oxygenation [26] . In an animal study, metaraminol had advantages over pure a-1 adrenergic agonists with respect to correction of fetal deterioration [27] . In a clinical trial it was superior to ephedrine in maintaining maternal systolic arterial pressure and neonatal umbilical artery pH [14] . Two previous studies have also compared metaraminol and phenylephrine [16, 17] . In a small study on elective caesarean section involving women of unspecified gestation, Bhardwaj et al. evaluated these drugs in a three-way comparison that included ephedrine. Using a phenylephrine-to-metaraminol potency ratio of approximately 15:1, no significant difference in neonatal acid-base outcome was found between the phenylephrine and metaraminol groups. Possibly due to unidentified confounders, both the umbilical artery and vein pH values were of lower magnitude than those found in our study. However, our results were consistent with those of Aragao et al. [16] , who compared the same three drugs in 90 women. They used a bolus before an infusion, with initial infusion rates for phenylephrine and metaraminol identical to those in our study. These investigators found no between-group differences with respect to neonatal outcomes or maternal haemodynamic status; however, their primary outcome was not clearly defined and no sample size calculation was performed [16] .
With respect to phenylephrine, an initial infusion rate of 25-50 lg.min À1 has been shown to provide the best balance in achieving effective control of maternal blood pressure without reactive maternal hypertension or bradycardia [8] [9] [10] 12] . In our study, many women experienced increases in blood pressure, more so in the metaraminol group. The high incidence in both groups probably reflects the study definition of hypertension as an increase in systolic arterial pressure to > 110% baseline. Such an increase is clinically unimportant in healthy women and was easily corrected by down-titration of the study drug, but suggests that this study regimen might be unsuitable for hypertensive women. The greater propensity to increased blood pressure with metaraminol may reflect the slower onset time of intravenous metaraminol, resulting in an over-shoot, or a mismatch in potency at the dosing rates used. The potency ratio of phenylephrine-to-metaraminol is not clear. We used an initial 5:1 dose ratio of metaraminol, consistent with previous studies [14, 16, 17] . Recent unpublished work in our unit suggests that the ratio for an infusion preventing maternal hypotension in 95% of cases is approximately 6:1. If so, our initial dose rates were close to equipotent, but favoured greater efficacy of phenylephrine. Potential pharmacodynamic differences aside, it could be argued that metaraminol has advantages over phenylephrine or noradrenaline in relation to the potential for drug error during its preparation for infusion. In our institution, both phenylephrine, supplied in 10 mg.ml À1 ampoules, and noradrenaline in 1 mg.ml À1 ampoules, require significant dilution before use at commonly used concentrations. Although pre-prepared syringes are commercially available, they are more expensive and have a shorter shelf life. Metaraminol is also provided in 10 mg.ml À1 ampoules, but requires only one dilution to obtain a clinically appropriate solution. Automated closed-loop feedback systems have been shown to be very effective at reducing the incidence of hypotension [28, 29] . Other study protocols, which did not use this technology, used a bolus of metaraminol before starting the same 250 lg.min À1 infusion that we did, and found lower rates of maternal hypotension and nausea [16, 17] . It may be that delivering a bolus dose before starting an infusion, or commencing infusions at a higher dose rate, may be warranted.
This study has some limitations. It was conducted during elective surgery in healthy term pregnant women and infants, so the findings may not apply to premature infants or to the non-elective setting. In addition, there were some failures to obtain adequate neonatal blood samples.
In conclusion, this is the largest clinical trial to compare phenylephrine and metaraminol for the prevention of hypotension during spinal and CSE anaesthesia at caesarean section; it lends further support to the premise that metaraminol is a suitable alternative to phenylephrine. Our finding of improved neonatal acid-base status after metaraminol was unexpected; although it may represent an a-error, this justifies further investigation of metaraminol in this setting.
